The detection of hepatitis C virus (HCV) in saliva was studied. Twenty-three subjects with chronic HCV infection and 1 subject with acute HCV infection were enrolled in a 21-day study. Roche COBAS Amplicor and Bayer VERSANT HCV RNA qualitative assays were used. For the 23 subjects with chronic HCV infection, 72% of 474 saliva samples were positive (or were imputed to be positive) for HCV RNA. Serum HCV RNA load predicted the detection of HCV RNA in saliva (odds ratio of 378.7 [95% confidence interval, 18.9-9996.6] for each additional log 10 value). This association was also observed in 1 subject with acute HCV infection. Thus, our data demonstrate that salivary HCV RNA detection was associated with serum HCV RNA load in individuals who were chronically or acutely infected with HCV.
B R I E F R E P O R T
High Serum Hepatitis C Virus (HCV) RNA Load Predicts the Presence of HCV RNA in Saliva from Individuals with Chronic and Acute HCV Infection transmission has been suggested by a handful of reports. Two cases of acute hepatitis C occurring after bites from HCVinfected individuals have been reported [4, 5] . In addition, one study has described acute hepatitis in a chimpanzee after subcutaneous inoculation of saliva from a chimpanzee with non-A, non-B hepatitis [6] . Studies using polymerase chain reaction (PCR)-based assays to detect HCV RNA in saliva have reported varying results, with detection rates ranging from 0% [7] to 100% [8] . None of these salivary studies include data that demonstrate the infectiousness of the HCV RNA detected in saliva. Two studies that assayed for negative-stranded HCV RNA reported the absence of this replicative intermediate in saliva [9, 10] . However, one study of patients with chronic sialadenitis (or Sjogren syndrome) reported the detection of negativestranded HCV RNA and HCV core antigen in salivary-gland tissue from all 8 patients studied [11] .
To date, all published studies of mucosal HCV shedding rates have been cross-sectional in design, and few have investigated potential cofactors of salivary HCV RNA detection. Studies of HIV, herpes simplex virus, and human herpesvirus 8 shedding have demonstrated that cross-sectional designs may substantially underestimate the true prevalence of viral shedding in body fluids [12] . Thus, we performed a longitudinal study that included daily self-collection of saliva samples by subjects with chronic HCV infection and by a subject with acute HCV infection, to more accurately define the frequency and pattern of HCV RNA detection in human saliva.
Subjects, materials, and methods. Subjects with chronic hepatitis C were recruited from the Hepatitis and Liver Clinic at Harborview Medical Center in Seattle, Washington. All of the subjects had detectable serum HCV RNA loads at baseline. The subjects collected saliva for 21 consecutive days by spitting into sterile collection containers every morning at home before eating or brushing their teeth and then immediately placing the containers into their home freezers. On day 21, the containers were transported on dry ice to the University of Washington Viral Hepatitis Laboratory and stored at Ϫ80ЊC until testing.
One nurse with acute hepatitis C infection collected saliva for 56 days. This subject was negative for anti-HCV and had an undetectable serum HCV RNA load with normal liver enzyme levels on the day of a needlestick injury; ∼5 weeks after the injury, the subject had developed an elevated alanine aminotransferase (ALT) level that peaked at 3190 U/L and a serum HCV RNA load that peaked at 54,383,480 IU/mL. The HCV RNA had cleared and the ALT level had normalized without Figure 1 . Detection of hepatitis C virus (HCV) RNA in saliva in 23 subjects with chronic HCV infection. Subjects are ranked by increasing baseline serum HCV RNA titer. Home self-collection of saliva samples was performed on 21 consecutive days. Serum HCV RNA load was found to be strongly associated with an increased odds of detecting HCV RNA in saliva-for each additional log 10 value, the odds ratio was 378.7 (95% confidence interval, 18.9-9996.6). White boxes indicate positive saliva samples; shaded boxes indicate negative saliva samples; black diamonds indicate that the saliva samples were of insufficient quantity to repeat testing with the transcription-mediated amplification assay, and so data were imputed; and "M" indicates missing samples.
treatment by 4 months. The subject was positive for anti-HCV 6 months later.
The present study was approved by the Institutional Review Board at the University of Washington. Informed consent was obtained from all study participants.
Two protocols were used to detect HCV RNA in the previously frozen saliva samples. The first employed the reversetranscription PCR-based qualitative Roche COBAS Amplicor assay (version 2.0; Roche Molecular Systems) [13] , using 200 mL of undiluted saliva. Because of the high rate of assay inhibition found in saliva samples with this method, a second protocol was developed using the transcription-mediated amplification (TMA)-based Bayer VERSANT HCV RNA qualitative assay. Saliva samples were thawed, diluted 1:1 with PBS, and treated with 0.2 mg/mL of pronase (Calbiochem) for 30 min at 37ЊC before assaying, in accordance with the manufacturer's instructions.
For the first 11 subjects enrolled (10 with chronic and 1 with acute HCV infection), saliva samples with uninterpretable or negative results by the Amplicor assay were retested using the second protocol. Some samples had no visible saliva remaining after Amplicor testing and were considered to be of insufficient quantity for retesting by the TMA assay. Because HCV RNAcontaining serum samples that test positive by the Amplicor assay have been found to have 99.9% concordance with results from the TMA assay in our laboratory (data not shown), samples that were positive by the Amplicor assay were not retested by the TMA assay. For the last 13 subjects enrolled, saliva samples were analyzed by the second protocol only.
Serum HCV RNA titers were measured using the Bayer Quantiplex HCV RNA 2.0 assay. Testing for hepatitis B surface antigen was performed using the Abbott Auzyme assay. Serologic assays for anti-HIV and anti-HCV were performed using the Genetic Systems HIV-1/HIV-2 Peptide EIA (Bio-Rad Laboratories) and the Abbott HCV EIA 2.0 diagnostic kit. Genotype testing was performed using a restriction fragment-length polymorphism assay.
HCV RNA-positive saliva samples were defined as those positive by either the Amplicor assay or the TMA assay. Rates of salivary HCV RNA detection were calculated as the number of days on which a positive sample was collected divided by the total number of days on which a sample was collected. For 35 samples that were negative by the Amplicor assay but that lacked sufficient quantity for the TMA assay, the number of days on which a sample would have been positive by the TMA assay was imputed. Nine samples that were missing because subjects did not collect saliva on that day were treated as missing data.
Imputation was performed on a subject level, when possible. Six subjects who had samples not tested by the TMA assay because of insufficient quantity had samples with sufficient quantity from other days that were tested by the TMA assay, and the proportion of the sufficient samples with negative Amplicor assay results that were positive by the TMA assay was calculated. For days with insufficient samples, this proportion was used to estimate the probability that a sample would have been positive by the TMA assay given a negative Amplicor assay result. This probability was then used to randomly generate binomial variables for the estimated number of positive TMA assay results among the insufficient samples. For the one subject who did not have any Amplicor assay-negative samples with TMA assay results, we used the population average to determine the positivity rate. Following the guidelines for multiple imputation, we computed 3 different random values for the number of days on which samples would have been positive by the TMA assay per the number of days with insufficient samples.
To estimate the overall number of days on which salivary HCV RNA was detected, the mean of the 3 imputed values was added to the observed number of days with positive samples. Generalized linear models with the binomial distribution and logit link were used to explore any association between rates of salivary HCV RNA detection and sex, age, and serum HCV RNA load. In these models, the scale parameter was adjusted for overdispersion. This analysis was performed with each of the 3 different imputations contributing to the total number of days on which positive samples were collected per person. Final-model results report the average of the coefficients from the 3 models. Confidence intervals (CIs) were constructed using the lower and upper limits from the 3 models giving the widest interval.
Results. The sensitivity of the Amplicor assay for serum is 100 IU/mL. To evaluate the sensitivity of the assay for detecting HCV RNA in saliva, we performed five 10-fold serial dilutions of HCV RNA-containing serum (titer, 2,000,000 IU/mL) from a genotype 1a-infected subject aliquotted into 8 saliva samples from 6 HCV-seronegative volunteers. All samples were positive at 20,000 IU/mL, and none were positive at !200 IU/mL. Thus, it appears that testing for HCV RNA in saliva is less sensitive than testing in serum. In addition, testing of saliva from 20 HCVseronegative control volunteers yielded no positive results.
Of the 207 saliva samples from the first 10 subjects with chronic HCV infection, 55 (27%) yielded uninterpretable results by the Amplicor assay because of assay inhibition. To reduce inhibition, we diluted the saliva 1:1 with PBS, added 0.2 mg/mL of pronase, and measured HCV RNA using the TMA assay, which has a published sensitivity of 5-10 IU/mL for serum HCV RNA [14] . Eight saliva samples from 4 HCVseronegative control volunteers were negative for HCV RNA by the TMA assay. The sensitivity of this assay for detecting HCV was tested using 10-fold serial dilutions of HCV RNAcontaining serum (titer, 2,000,000 IU/mL), as described above. All samples were positive at 200 IU/mL, and none were positive at !20 IU/mL. Thus, the TMA assay appears to be at least 10-fold more sensitive than the Amplicor assay for detecting HCV RNA in saliva, even after dilution with PBS.
Of the subjects with chronic HCV infection who self-collected saliva samples at home on 21 consecutive days, 8 were men and 15 were women. The median age of the subjects was 49 years (range, 27-67 years). One subject was HIV seropositive. Eleven subjects had genotype 1a infection, 8 had genotype 1b infection, 2 had genotype 3a infection, 1 had genotype 2b infection, and 1 subject's virus isolate was not typeable. Subjects had mild to moderate liver inflammation, with a median ALT level of 54 U/L (range, 16-225 U/L), and all had intact hepatic synthetic function, with a median albumin level of 4.0 g/dL (range, 3.2-4.9 g/dL).
A total of 474 saliva samples were collected, with only 9 (2%) days of collection missed by all 23 subjects. HCV RNA was detected in 320 (73%) of 439 samples that had sufficient volume for testing. Adding the imputed data for the 35 saliva samples that were negative by the Amplicor assay, 342 (72%) of 474 samples were estimated to be positive for HCV RNA.
Of the 23 subjects studied, 22 (96%) had HCV RNA detected in saliva on at least 1 day. The pattern of detection by subject and baseline serum HCV RNA load is shown in figure 1 . In univariate regression models, age, sex, and genotype were not associated with the detection of HCV RNA in saliva, whereas baseline serum HCV RNA load was strongly associated with an increased odds of detecting HCV RNA in saliva-for each additional log 10 value, the odds ratio (OR) was 378.7 (95% CI 18.9-9996.6).
We also had the opportunity to study the detection of HCV RNA in saliva in 1 additional subject, who presented 35 days after a needlestick injury with an elevated ALT level. This subject shed HCV RNA in saliva on 16 of the first 17 days of collection. Her serum HCV RNA loads were extremely high during this time period (figure 2). After the 17th day of collection (52nd day of infection), HCV RNA was not detected in saliva, despite the collection of samples for an additional 39 days. During this time, serum HCV RNA loads were likely decreasing rapidly; spontaneous clearance of serum HCV RNA was documented 102 days after the needlestick injury.
Discussion. HCV RNA was detected (or was imputed to be present) in 342 (72%) of 474 saliva samples from subjects with chronic HCV infection, and a high serum HCV RNA load was a strong predictor of detection of HCV RNA in saliva (OR of 378.7 [95% CI, 18.9-9996.6] for each additional log 10 value). The association between serum HCV RNA load and detection of HCV RNA in saliva was also seen in a subject with acute HCV infection, who had HCV RNA detected in saliva early during the clinical course of infection, when her serum HCV RNA load was the highest, with no further detection after a rapid decrease in serum HCV RNA load.
Our data help to explain why point prevalences and longitudinal studies of mucosal HCV shedding may yield disparate results and demonstrate that salivary HCV shedding is dynamic. The association between serum HCV RNA level and mucosal shedding appears to vary during the course of infection. Furthermore, HCV RNA is more frequently present in the saliva of individuals with high serum HCV RNA loads. Thus, clinical factors that are associated with high serum HCV RNA loads, such as acute HCV infection or HIV/HCV coinfection, may be expected to result in more-frequent detection of HCV RNA in saliva.
Although our data clearly show that HCV RNA is present and often persistent in the saliva of HCV-infected individuals, the mechanism of HCV shedding in saliva and the role that salivary HCV RNA plays in the actual transmission of infection to others remain undefined. Multiple factors contribute to the infectivity of body fluids, including the presence of intact and infectious viral particles, the viral titer, and the presence of appropriate target cells in the exposed area of the uninfected individual. Epidemiologic data do not support the concept that HCV is efficiently transmitted through saliva. However, toothbrushes have been implicated as a vehicle for HCV transmission in several studies [15] . Our findings lend biological plausibility to the hypothesis that salivary HCV transmission may occur under certain circumstances, but our results must be interpreted with caution, to avoid unnecessary stigmatization of HCV-infected individuals.
